Chronic Inhibition of ERK1/2 Signaling Improves Disordered Bone and Mineral Metabolism in Hypophosphatemic (Hyp) Mice

Martin Y. H. Zhang(University of California, San Francisco), Farzana Perwad(University of California, San Francisco)

Endocrinology

February 14, 2012

10.1210/en.2011-1831

Cited by 53

Related Papers

Continued Beneficial Effects of Burosumab in Adults with X-Linked Hypophosphatemia: Results from a 24-Week Treatment Continuation Period After a 24-Week Double-Blind Placebo-Controlled Period

|Calcified Tissue International|2019|160

FGF-23 Regulates CYP27B1 Transcription in the Kidney and in Extra-Renal Tissues

|PLoS ONE|2013|80

Burosumab treatment in adults with X-linked hypophosphataemia: 96-week patient-reported outcomes and ambulatory function from a randomised phase 3 trial and open-label extension

|RMD Open|2021|72

Fibroblast growth factor 23 regulates renal 1,25-dihydroxyvitamin D and phosphate metabolism via the MAP kinase signaling pathway in <i>Hyp</i> mice

|Journal of Bone and Mineral Research|2011|68

Characterization of FGF23-Dependent Egr-1 Cistrome in the Mouse Renal Proximal Tubule

|PLoS ONE|2015|31